10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 328 filers reported holding 10X GENOMICS INC in Q3 2021. The put-call ratio across all filers is 2.03 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $490,627 | -65.9% | 11,894 | -53.8% | 0.00% | -66.7% |
| Q2 2023 | $1,437,097 | -17.3% | 25,736 | -17.4% | 0.00% | 0.0% |
| Q1 2023 | $1,738,302 | +57.6% | 31,158 | +2.9% | 0.00% | +50.0% |
| Q4 2022 | $1,103,328 | +1708.7% | 30,278 | +1290.2% | 0.00% | – |
| Q3 2022 | $61,000 | -99.6% | 2,178 | -99.4% | 0.00% | -100.0% |
| Q2 2022 | $16,038,000 | -44.3% | 354,481 | -6.4% | 0.03% | -34.0% |
| Q1 2022 | $28,808,000 | -22.2% | 378,757 | +52.4% | 0.05% | -15.3% |
| Q4 2021 | $37,032,000 | -8.3% | 248,608 | -10.4% | 0.06% | -13.2% |
| Q3 2021 | $40,402,000 | -27.1% | 277,550 | -1.9% | 0.07% | -26.9% |
| Q2 2021 | $55,422,000 | +18.5% | 283,044 | +9.5% | 0.09% | +12.0% |
| Q1 2021 | $46,776,000 | +4707.4% | 258,446 | +3665.8% | 0.08% | +4050.0% |
| Q4 2020 | $973,000 | +112.9% | 6,863 | +34.0% | 0.00% | +100.0% |
| Q2 2020 | $457,000 | +284.0% | 5,121 | +166.4% | 0.00% | – |
| Q1 2020 | $119,000 | – | 1,922 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Venrock Management VI, LLC | 962,309 | $188,439,000 | 95.08% |
| Foresite Capital Management II, LLC | 1,753,528 | $343,376,000 | 92.37% |
| Foresite Capital Management I, LLC | 750,000 | $146,865,000 | 88.53% |
| 12 West Capital Management LP | 1,922,000 | $376,366,000 | 15.78% |
| Financial Consulate Inc. | 141,258 | $27,661,000 | 9.97% |
| FINANCIAL CONSULATE, INC | 141,258 | $27,661,000 | 9.97% |
| Meritech Capital Associates V L.L.C. | 1,793,871 | $351,276,000 | 7.51% |
| Andar Capital Management HK Ltd | 51,000 | $9,987,000 | 6.81% |
| JS Capital Management LLC | 540,589 | $105,858,000 | 5.12% |
| Renaissance Capital LLC | 97,281 | $19,050,000 | 3.01% |